Please assess the completion status of the following clinical trial:

Trial Title: Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* documented CHB infection with HBsAg positive \> 6 months~* HBeAg+ CHB pregnant women~* gestational age between 30-32 weeks~* HBV DNA \> 6 log10 copies/mL (or \>200,000 IU/mL)~* both mother and father of the child are willing to consent for the study~Major Exclusion Criteria:~* co-infection with hepatitis A, C, D, E, HIV-1 or sexually transmitted disease (STD)~* decompensated liver disease or significant co-morbidity~* history of abortion, or diagnosis of fetal defect, or congenital malformation in prior pregnancy~* antiviral used within six months prior to this pregnancy, or history of renal or tubular function impairment due to adefovir.~* requirement for other medication during pregnancy to manage other chronic disease(s) or concurrent treatment with immune-modulators, cytotoxic drugs, or steroids~* the biological father of the child had CHB~* clinical signs of threatened miscarriage in early pregnancy~* evidence of hepatocellular carcinoma~* maternal alanine aminotransferase (ALT) \> or = 5 x upper limit of normal (U/mL), or Total Bilirubin \> or = 2, or glomerular filtration rate (GFR) \< 100, or Albumin \< 25 g/L~* evidence of fetal deformity by ultrasound examination~* patient is participating other clinical study

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Control arm: HBIG & vaccine for infants (Type: NO_INTERVENTION): Provide standard of care to mothers and standard immunoprophylaxis to their infants
- TDF treatment arm (Type: EXPERIMENTAL): tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum for mothers and standard immunoprophylaxis to their infants

Based on this trial design, predict the completion outcome and termination type (if applicable).